Industry - acib

FROM IDEA TO INNOVATION

acib has built up a network of numerous small, middle and large sized industry partners coming from several sectors of industrial biotechnology. Most of them joined the COMET consortium, but – as COMET is temporary and monetary limited – acib also has opportunities for alternate collaboration possibilities.

An attractive offer for our stakeholders from industry is the academic partner network, which allows industrial organizations to consume R&D activities from a tailored research expertise portfolio coming from currently 53 scientific partners.

acib AS TARGETED-RESEARCH-HUB

acib’s position as a targeted-research-hub for industrial biotechnology will be further developed. In combining all partners and networks in a new contractual acib partner network, acib is able to fulfill its mission of connecting the worlds from academia and industry for innovation and science-know-how. Thus acib is a one-stop-shop and ideal partner for Open Innovation.

CURRENT OFFERS – RESEARCH MARKET PLACE

acib offers new technologies, expertise and project concepts. Please keep up-to-date with our latest offers by subscribing to our newsletter. For further information please contact Martin Trinker.

59 / PROJECT OFFER

Recombinant Protein Production

24.08.2020

58 / PROJECT OFFER

Protein Engineering

24.08.2020

57 / PROJECT OFFER

Biotechnological synthesis of pure ingredients of natural essential oils

20.05.2020

56 / PROJECT OFFER

Discovery platform for antiviral agents to SARS-CoV-2 and other high risk pathogens in a BSL-3+ laboratory

19.05.2020

55 / PROJECT OFFER

endSARS

15.04.2020

54 / PROJECT OFFER

ProFabSARS

15.04.2020

53 / PROJECT OFFER

SARS-CoV-2 monoclonal antibodies

08.04.2020

52 / PROJECT OFFER

SARS-CoV-2 glycoprotein expression

08.04.2020

51 / PROJECT OFFER

KINaCoV-2

08.04.2020

50 / PROJECT OFFER

CURES – SARS-CoV-2

01.04.2020

49 / PROJECT OFFER

MUTATRACER – SARS-CoV-2

01.04.2020

48 / PROJECT OFFER

HOPE – SARS-CoV-2

01.04.2020

47 / TECHNOLOGY OFFER

Enzymatic treatment of tumble dryer residues

11.02.2020

46 / TECHNOLOGY OFFER

Enzymatic baby diapers recycling

11.02.2020

45 / PROJECT OFFER

Biocatalytic valorisation of fatty acids

14.01.2020

44 / PROJECT OFFER

Contact-based antimicrobial (nano)materials

14.01.2020

43 / PROJECT OFFER

Rainbow Cell Technologies

3.04.2019

42 / PROJECT OFFER

Fighting Biofilms

12.02.2019

41 / PROJECT OFFER

CO₂-Recycling and Biopolymers

09.01.2019

40 / PROJECT OFFER

(Micro)plastic degradation

09.01.2019

39 / PROJECT OFFER

Bioleaching / Bioremediation

09.01.2019

38 / PROJECT OFFER

Enzyme discovery and development for polymer processing

13.12.2017

37 / PROJECT OFFER

3D Phase Contrast Microscopy for Flow Cytometry

13.12.2017

36 / PROJECT OFFER

Improving the immunogenicity of vaccines

13.12.2017

35 / TECHNOLOGY OFFER

Up-regulation of protein expression through use of RNA polymerase binding aptamers (RAPS)

21.11.2017

34 / PROJECT OFFER

Making nanoparticles more stable for biological environments

20.11.2017

33 / SERVICE OFFER

Smart library approaches employing the BioXP^TM 3200 platform

13.11.2017

32 / PROJECT OFFER

Bacterial Natural Product Optimization via Biosynthetic Engineering and Medicinal Chemistry

13.06.2017

31 / PROJECT OFFER

Project on Antibacterial Antibiotic Discovery and Development

13.06.2017

30 / CO-DEVELOPMENT OFFER

Inhibition of gene expression from “foreign DNA”

13.06.2017

29 / PROJECT OFFER

BioF&F – Biotechnological production of Flavor & Fragrance compounds

30.03.2017

28 / PROJECT OFFER

BOSS – Biotechnological Optimizations by Selection Systems

29.03.2017

27 / PROJECT OFFER

Biocatalytic methylation and demethylation of phenol derivatives

24.03.2017

26 / PROJECT OFFER

Lactic Acid Production

25 / PROJECT OFFER

Biorefinery Solutions

10.03.2017

24 / PROJECT OFFER

Photo-BioPolymers

10.03.2017

23 / CO-DEVELOPMENT OFFER

GISS – Gastro Intestinal Simulation System

22 / TECHNOLOGY OFFER

Compact and optimized metabolic pathway design in yeasts

16.02.2017

21 / SERVICE OFFER

Assembly of multi-part DNA constructs

26.01.2017

20 / SERVICE OFFER

Metabolomics

19.01.2017

19 / SERVICE OFFER

13-C labeled metabolite extract

19.01.2017

18 / PROJECT OFFER

Towards the next generation of industrial bioethanol production

19.01.2017

17 / PROJECT OFFER

Project offer: Towards the Next Generation of Lignocellulose-Based Industrial Biomanufacturing

19.01.2017

16 / PROJECT OFFER

Biotechnological synthesis of natural insect repellents

17.01.2017

15 / PROJECT OFFER

Continuous biocatalysis using liquid membrane technology

13.12.2016

14 / SERVICE OFFER

Bioinformatics

13.12.2016

13 / COMPETENCE OFFER

Biocatalytic Synthesis and Enzyme Technology

18.11.2016

12 / PROJECT OFFER

Enzymatic Alkene Cleavage

28.10.2016

11 / PROJECT OFFER

Biotechnological preparation of chitin and chitosan from shrimp shell waste

25.10.2016

10 / TECHNOLOGY OFFER

3D Enzyme Search

9 / PROJECT OFFER

Synthesis of bio-based resveratrol analogues

23.08.2016

8 / PROJECT OFFER

Combinatorial pathway assembly for Green Chemistry

26.07.2016

7 / SERVICE OFFER

Directed modification of proteins using unnatural amino acids

26.07.2016

6 / CO-DEVELOPMENT OFFER

Drug Resistance

18.07.2016

5 / TECHNOLOGY OFFER

Novel Hydroxynitrile Lyases

05.07.2017

4 / PROJECT OFFER

Antibacterial Antibiotic Discovery and Development – AntiBac

20.06.2016

3 / PROJECT OFFER

Bacterial Natural Product Optimization via Biosynthetic Engineering and Medicinal Chemistry – BacTech

1.06.2016

2 / TECHNOLOGY OFFER

Biocatalytic Friedel-Crafts Acylations

25.05.2016

1 / TECHNOLOGY OFFER

Nanomembranes

11.02.2016

“The close and trusting collaboration with acib’s academic partners is a constant source of new and valuable stimulus for the development of innovative metabolic pathways and novel reactor designs for optimal performance of the functionalization of alkanes.”

Bastian Grund / Project Manager Evonik
“Our acib partners … are doing a thorough work. They pursue the project with diligence and a good sense for focusing on the important issues to be solved. It is a pleasure to collaborate with such a competent team and see continuous progress in achieving the project’s goals.”

Dr. Judith Wahrheit / Contract Research Biocrates
“Our collaboration with acib has so far proven to be very productive and has resulted in a number of exciting technical applications. The scientific team members are highly qualified and really motivated to pursue their objectives.”

Dr. Christa Tauer / Head of Bio OpU Process Development Shire
“The wide spectrum of acib competence and skills in techniques and methods of acib experts is a unique basis for the realization of our product visions at the crossroads between minerals and biotechnology.”

Gernot Tauterer / Research Director IPUS
“We are pleased with the long-lasting collaboration with acib. The open and creative atmosphere and the in general excellent results obtained have over the years contributed to the successful implementation of several industrial process in the production of chemical intermediates at DSM.”

Dr. Martin Schürmann / Principal Scientist DSM
“In all phases of the project we had a very fruitful and open minded communication and the team was always helpful and dedicated to make it a success. Now the 3rd project in a row is being planned and Novartis will benefit from all the knowledge and very good outcome implemented and use it for process optimization and developmental purposes.”

Ernst Neuhauser / Lead DS Operational Mgmt. Novartis
“acib stands out due to the huge pool of multidisciplinary expertise and capabilities available for its industrial partners across the entire field of industrial biotechnology.”

Dr. Thomas Purkarthofer / Head of Business Development Validogen (formerly VTU Technology)
“The collaboration with acib and its constituting body of experts in biotechnology in the framework of a funded R&D competence centre enables us to engage in high-risk potentially high-reward research. We greatly appreciate this opportunity.”

Dr. Patrick Lorenz / Head of Molecular Biology AB Enzymes
“The acib collaboration enables rapid and straight-forward research on current requirements of the Roombiotic product pipeline. I personally recommend acib to biotech start-ups as powerful and reliable partner in challenging research projects.”

Dr. Daniel Treffer / CEO Roombiotic
“This is the perfect match: research focus to the company´s interest and professional acib partners to collaborate combined with the acib co-funding and administrational support creating the attractive research programme base.”

Dr. Terhi Puranen / R&D Manager Roal Oy
“While having grown to a large organization, acib still provides a highly professional and responsive collaborative research environment capable of quickly reacting to specific project needs.”

Dr. Peter Pöchlauer / Patheon Austria GmbH & Co KG
“acib’s broad expertise in biocatalysis provides a valuable contribution to our research activities. We greatly appreciate the open and fruitful collaboration with acib’s research team, that improves our knowledge and shortens the development period of our ambitious projects.”

Dr. Jürgen Kuballa / CEO GALAB
“The acib collaboration provides an important contribution to Sandoz’s new technology evaluation & development programs.”

Dr. Sascha Keller / Head of Downstream Process Development Sandoz
“The current cooperation with acib provides an essential and valuable contribution to create new possible value propositions for our products. Thanks for a job well done.”

Dr. Kurt Eyer / Technical Manager 3M
“The collaboration with acib enables us to access state-of-the-art technologies in the field of industrial biotechnology in general and above all in recombinant protein expression. The entire acib project team is dedicated and driven in their ambitions to achieve the project goals. The research performed by acib is excellent and complementary to our own research and greatly appreciated at BIOMIN.”

Dr. Lukas Sturmberger / Project Leader Biomin
“With the highly engaged acib team the ambitious goals to develop a set of technologies for continuous processing of complex and sensitive molecules could be achieved. Together we could overcome serious challenges and set the base for implementation of some technologies at development/pilot scale and finally also into commercial processes.”

Dr. Martin Purtscher / Senior Expert Takeda
“acib is a very important R&D partner for Clariant Group Biotechnology in the field of academic cooperation and was chosen because of its specific expertise in Clariant’s fields of interest and current activities. acib provides research expertise which is at the forefront of experimental R&D state of the art, enabling up-to-date research work. acib has broad expertise in various fields of industrial biotechnology (strategic fit to industry needs).”

Dr. Georg Schirrmacher / Scientific Coordinator Clariant
“Results generated within acib were implemented into our product development program. We appreciate the solution-oriented research focus.”

Dr. Nora Temme / KWS Saat
“We run a research project with acib to create a new and innovative route to an existing active pharmaceutical ingredient (API). acib investigated on critical step in the synthesis. They brought in great experience, a very systematic approach and – most importantly – a tremendous drive to get the project done. acib offers excellent research capabilities in all relevant fields. We are already preparing a new project with acib.”

Dr. Kai Donsbach / CTO, Global Head R&D PharmaZell
“acib is the foundation of our collaboration strategy in Austria. The projects we undertake within the framework in both Vienna/Tulln and Graz are essential to our innovation strategy. The quality and continuity of the programs are first rate while the overall context and connectivity that one experiences in parallel add a great deal to the experience.”

Michael Burnet / Managing Director Synovo
“The current cooperation with acib provides an essential and valuable contribution to improve our existing manufacturing process. The theoretical and practical knowledge provided by acib are key parameters that will bring our joint project to success.”

Dr. Matthias Müllner / Head of Manufacturing Themis Bioscience
“Our research and development progress would have been impossible without the collaboration with acib. acib complements our expertise to create a world class laboratory that can execute experiments at a high level. And, when we go to share results, acib’s stellar reputation ensure others have confidence in our data.”

Edward Eveleth / Chairman HocusLocus
“acib facilitates in a highly professional and efficient manner the collaboration of people from two different worlds, academia and business. Knowing the different mindsets from both sides, acib is a valuable partner in helping to translate the needs and visions of both company and academic partners into a successful joint R&D cooperation.”

Gerald Ruppert / IP Manager Viscose Faser
“acib provides excellent research opportunities and advantages, enabling companies to keep pace with the rapid scientific progress.”

Dr. Henry Müller / CEO Biotenzz
“We are working with acib successfully since 2010. Our long running collaboration with acib is built on trust and a genuine interest in each other’s progress. The collaboration has been very fruitful in both directions and continues to do so due to its strong communication, versatility and adaptability.”

Dr. Daniel Koch / Head of Strain Development Jungbaunzlauer Austria AG
“We have had a great collaboration with our colleagues at acib and we have learned a lot.”

Dr. Ann Lövgren / Principal Scientist GE Healthcare
“We are working with acib since 2012. The results are exceeding our expectations and thus increase our competitiveness in the international biotechnology-market. We value the high competence and expertise of acib scientists, as well as the open and constructive discussions marked by trust and leading to pioneering innovations.”

Otto Kanzler / CEO Chorus
“As a pretty young company in the field of biolife-science we appreciate the close cooperation with the absolute experts of acib.”

Peter Pucher / Head of R&D BDI – BioLife Science